前立腺肥大症の姑息的療法 gestagen療法

Abstract

Recently, gestagen therapy is made attempt as a new approach to the endocrine control of benign prostatic hypertrophy (EPH). Twenty-five patients of BPH in our clinic (out-patients 14, in-patients 11) were treated with Gestonorone Caproate (SH 582), a new strong progestational agent developed by Schering AG Berlin. 200-600 mg/week of SH 582 were injected in the outpatients for 45-90 days and 200-300 mg/day of SH 582 were injected in the in-patients daily for 10-25 days. Residual urine, urinary stream, dysuria and nycturia were examined as to clinical effect. The best improvement of residual urine was observed in stage II series of BPH receiving 600 mg/week injection (3/5). Urinary stream, dysuria and nycturia improved in stage II patients of BPH that were given 400-600 mg/week or 200 mg/day injection (6-7/19). Side effects were found in two patients, one was anorexia, another was impotence. Abnormal change of blood-picture, liver function, renal function and serum acid-phosphatase after injection of SH 582 were not observed. The results of endocrine studies such as urinary total gonadotropin, neutral 17 KS, 3 fraction of estrogen and 17 OHCS were as follows: Gonadotropin was inhibited by administration of large dose of SH 582. 17 KS decreased slightly and estrone increased about two times to pretreatment level by SH 582. 17β-estradiol was not changed. Estriol and 17 OHCS increased slightly after injection. The histological findings of prostate were not changed particularly on operated patients (6 cases). In conclusion, Gestonorone Caproate can be used without detestable side effects for conservative treatment of some selected cases of BPH such as early stage or under the poor general condition etc.